Accessibility links Skip to main content

QTAs (Quality Technical Agreements) Best Practices

The Quality Technical Agreement (QTA) is a formal quality document that is written and approved between 2 parties (the party that provides the service/product and the party that receives it). The document defines in detail the GMP responsibilities, including the quality measure of each party.

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading

The importance of QTAs

  • Regulatory compliance: ensure that all manufacturing and supply activities comply with legal and regulatory requirements.
  • Quality assurance: maintain the quality of products by defining clear quality specifications and standards.
  • Risk management: outlining roles and responsibilities, QTAs mitigate risks associated with outsourcing and supply chains.
  • Transparency: establish transparent communication between all parties, facilitating smooth operations and conflict resolution.

Quality Technical Agreements (QTAs) are not just a nice-to-have; there is a regulatory requirement to have them established!

QTAs are established with manufacturers, suppliers and service providers to obtain written agreements of the details of activities to be provided and the associated requirements and controls. Each agreement type should be tailored to address the relevant aspects of the particular type of relationship.

Manufacturing quality agreements are established between parties involved in the contract manufacture of medicinal products; such an agreement will define and establish each party’s manufacturing activities in terms of how each party will manufacture product in compliance with cGMPs and the Marketing Authorisation. Supplier quality agreements on the other hand are established to define the terms and conditions relating to the quality of materials or services supplied to a manufacturing facility that are used in the products or in the production of products. Service quality agreements, as their name indicates, define the terms and conditions relating to the quality of services supplied to a manufacturing facility that are used in the production of products.  Any outsourced contract arrangement should have an associated quality agreement; this includes arrangements between different divisions of the same company, or between sister companies.

QTAs must be written in such a manner to ensure no ambiguity and that roles and responsibilities, including communication channels and timelines, are clear and understood by both parties. A procedure should exist on the requirements for QTAs within your organisation. This should define the review period of all QTAs which should be assessed during PQS management reviews, after which updates are processed as applicable.

The ICH Guide clearly states that “there should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measure of each party”. In addition, Eudralex provides “A Contract should be drawn up between the Contract Giver and the Contract Acceptor which specifies their respective responsibilities and communication processes relating to the outsourced activities. Technical aspects of the Contract should be drawn up by competent persons suitably knowledgeable in related outsourced activities and Good Manufacturing Practice.” In addition, the GMP guidelines also state that “The Contract should describe clearly who undertakes each step of the outsourced activity, e.g. knowledge management, technology transfer, supply chain, subcontracting, quality and purchasing of materials, testing and releasing materials, undertaking production and quality controls (including in-process controls, sampling and analysis).

What should a QTA include?

Ensure all aspects that affect the identity, quality, safety, potency and purity of a product are included within the agreement. As a minimum, your QTA should include:

  • Purpose & scope
  • Definitions
  • Roles and Responsibilities (including contact details)
  • Dispute Resolution
  • Termination and survival
  • Communication methods
  • Documentation
  • Use of third-parties, if relevant
  • List of products associated with the agreement
  • Change & revisions
  • Ammendments

What are the key considerations when establishing a QTA?

1. Involve cross-functional personnel to review the document.

While the QTA should be prepared by the QA team, involving manufacturing, laboratory, supply chain and legal personnel for example is key to ensuring the document meets the appropriate requirements for all stakeholders.

2. Develop a framework checklist.

This framework document should include all key aspects of the QTA document and a review of the template against this checklist will identify gaps immediately. Forgetting to include a key point at the negotiation stage could lead to significant problems further down the track!

3. Examine the definitions and key terms for clarity.

When is a change a major change? Do all deviations need to be endorsed by both quality teams? How are out of specification results handled? Ensure the document is unambiguous in nature so roles and responsibilities are clearly defined.

4. Ensure the QTA is aligned with the Master Services Agreement (MSA) or Supply Agreement.

Whilst the MSA describes the financial and legal interactions, it does overlap with the QTA in operational areas and deliverables. Review both documents alongside each other to ensure no conflict exists.

5. Do a dry-run!

During the negotiation stage, test the QTA against a previous experience to see if you have sufficiently documented responsibilities, timelines, requirements etc. and assess if the QTA is adequate. For example, if notification of a deviation requires acknowledgment, agreement, approval- ensure this is stated clearly within.

Aside from being a regulatory requirement, quality technical agreements reduce errors, timelines and ultimately cost. Remember, just because you are outsourcing an activity, this does not relieve you of the responsibility associated. Leave nothing to chance and ensure your QTAs are in place today!

Your partner in quality, safety, and compliance

The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

QP Services

Clinical QP Services

Related articles

07 Apr 2026

MIAS Pharma will be attending the BIO International Convention in San Diego, USA

MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.

01 Apr 2026

Let’s Meet at SNMMI Annual meeting 2026 LA

MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.

20 Mar 2026

Labelling & Packaging: A Core MAH Responsibility

Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.

13 Mar 2026

Getting ready for product launch with serialisation

As your medicinal product moves from the clinical space into commercial launch territory, one crucial question looms large:

06 Mar 2026

MAHs: Are Your GMP–GVP Interfaces Aligned?

Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?

27 Feb 2026

MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.

20 Feb 2026

Quality & Regulatory Implications from EU Critical Medicines Act

The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.